Somalogic Inc (SLGC) - Total Liabilities
Based on the latest financial reports, Somalogic Inc (SLGC) has total liabilities worth $68.31 Million USD as of September 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SLGC year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Somalogic Inc - Total Liabilities Trend (2019–2022)
This chart illustrates how Somalogic Inc's total liabilities have evolved over time, based on quarterly financial data.
Somalogic Inc Competitors by Total Liabilities
The table below lists competitors of Somalogic Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Duratec Ltd
AU:DUR
|
Australia | AU$158.85 Million |
|
Nanyang Senba Optical and Electronic Co Ltd
SHE:300701
|
China | CN¥117.63 Million |
|
Delcath Systems Inc
NASDAQ:DCTH
|
USA | $12.13 Million |
|
Haleon PLC
LSE:HLN
|
UK | GBX15.83 Billion |
|
Shanghai Karon Eco-Valve Manufacturing Co. Ltd.
SHE:301151
|
China | CN¥551.16 Million |
|
Hyulim ROBOT Co.Ltd
KQ:090710
|
Korea | ₩73.45 Billion |
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
USA | $2.59 Million |
|
Tieling Newcity Investment Holding Ltd
SHE:000809
|
China | CN¥1.42 Billion |
Liability Composition Analysis (2019–2022)
This chart breaks down Somalogic Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SLGC market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Somalogic Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Somalogic Inc (2019–2022)
The table below shows the annual total liabilities of Somalogic Inc from 2019 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $84.82 Million | -9.85% |
| 2021-12-31 | $94.08 Million | +66.88% |
| 2020-12-31 | $56.37 Million | +10.88% |
| 2019-12-31 | $50.84 Million | -- |
About Somalogic Inc
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in … Read more